Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine + Duloxetine for Depression in Postherpetic Neuralgia
NCT06968624Phase 4Not yet recruiting
- Sponsor
- Huazhong University of Science and Technology
- Start
- Jun 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of esketamine in major depressive disorder (MDD), postherpetic neuralgia (PHN), sponsored by Huazhong University of Science and Technology. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT06968624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06968624.